Understanding obesity as a chronic disease helps reduce stigma and shift expectations. Treatment is not about willpower—it is about biology. Long-term therapy is not a failure; it is appropriate chronic disease management. Obesity is recognized as a chronic, relapsing disease. This indicates need for continued and life-long treatment. The natural history can include cycles of weight loss and weight gain. After weight loss there are powerful biological adaptations that defend

Many insurance companies are not paying for anti-obesity medications (AOM). There is a current Medicare law that directly affect Medicare patients. This law also indirectly influences other health insurance carriers. In some instances this can be overcome by treatment for a weight/obesity related condition. For patient patients wanting to start AOM with GLP, we completed a cost analysis based on the SURMOUNT 5 data and using prices from Eli Lilly direct prescriptions of Tirze

Rarely in medicine are their head to head trials of pharmaceuticals. In the Surmount 5 Trial, researchers directly compare Semaglutide vs Tirzepatide in a phase 3b trial. The comparison was specifically for obesity and excluded patients with diabetes. For 18 months, 751 adults were trialed on either Semaglutide or Tirzepatide. The results had significant weight loss for all participants. Tirzepatide had the most average weight loss. In fact, at the two max doses (10mg &15 mg)

GLPs offer powerful weight loss opportunity. For many, cost prevents access to treatment and some patients seek cheaper options through compounding. The Obesity Medical Association and this author recommend against use of compounded agents. There are safety considerations with compounded GLPs. Recently the FDA reported: 605 reports of adverse events associated with compounded semaglutide 545 reports of adverse events associated with compounded tirzepatide Is there a better op